Hamaluba M

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.Kibwana E, Bundi C, Kimani D, Nyamako L, Keter K, Mutiso A, Ogwang R, Bellamy D, Rapi K, Bajer A, Provstgaard-Morys S, Stockdale L, Munoz O, Datoo MS, Lawrie A, Ramos-Lopez F, Roberts R, Hamaluba M, Hill AVS, Bejon P, Ewer KJ, Kapulu M
Front Immunol, (2025). 16:1620365

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.Bundi C, Bellamy D, Kibwana E, Nyamako L, Ogwang R, Keter K, Kimani D, Salman AM, Provstgaard-Morys S, Stockdale L, Hill AVS, Bejon P, Olotu A, Hamaluba M, Ewer KJ, Kapulu MC
Front Immunol, (2025). 16:1620366

Early weaning from oxygen therapy in African children with severe pneumonia.Maitland K, Giallongo E, Hamaluba M, Alaroker F, Opoka RO, Tagoola A, Nalwanga D, Nabawanuka E, Okiror W, Nakuya M, Aromut D, Williams TN, Thomas K, Harrison DA, Mouncey P, Bush A, Fraser JF, Rowan K, Olupot-Olupot P, Kiguli S
BMC Med, (2025). 23:366

Supplementation with ready-to-use therapeutic food has no effect on adverse outcomes among undernourished children aged 6-59 months with severe pneumonia.Nalwanga D, Giallongo E, Musiime V, Kiguli S, Olupot PO, Alaroker F, Opoka R, Tagoola A, Hamaluba M, Mogaka C, Nabawanuka E, Karamagi C, Briend A, Maitland K
Front Nutr, (2025). 12:1507360

Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.Maitland K, Ouattara SM, Sainna H, Chara A, Ogundipe OF, Sunyoto T, Hamaluba M, Olupot-Olupot P, Alaroker F, Connon R, Saidou Maguina A, Okiror W, Amorut D, Mwajombo E, Oguda E, Mogaka C, Langendorf C, Dewez JE, Ciglenecki I, Gibb DM, Coldiron ME, Petrucci R, George EC
N Engl J Med, (2025). :

COVID-19 mortality in Africa and Asia - Authors' reply.Bejon P, Agweyu A, Oyier I, Hamaluba M, Kamuya D, Kinyanjui S, Barasa E
Lancet Infect Dis, (2025). :

Rethinking the evidence on COVID-19 in Africa.Bejon P, Agweyu A, Ochola-Oyier LI, Hamaluba M, Kamuya D, Kinyanjui S, Barasa E
Lancet Infect Dis, (2025). 25:S1473-3099

Investigating the dynamics of Plasmodium falciparum gametocyte carriage in expectant women under intermittent preventive treatment with sulfadoxine-pyrimethamine in Kilifi, study protocol.Kiyuka PK, Muricho M, Ouma N, Muiruri C, Nyaguara A, Rono M, Oyier I, Hamaluba M
Open Res Eur, (2025). 5:60

Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults.Abouyannis M, Nyambura YK, Ngome S, Riako D, Musyoki J, Muiruri C, Orindi B, Else L, Amara A, Dickinson L, Clare RH, Albulescu LO, Westhorpe AP, Kool J, Adetifa I, Ndungu FM, FitzGerald R, Khoo S, Lalloo DG, Casewell NR, Hamaluba M
EBioMedicine, (2025). 113:105600

Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.Gallagher KE, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, Mwalekwa L, Ragab S, Twi-Yeboah L, Berkley JA, Hamaluba M, Karani A, Shangala J, Otiende M, Gardiner E, Mugo D, Smith PG, Tabu C, Were F, Goldblatt D, Scott JAG
N Engl J Med, (2024). 391:2003-2013

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.Schilling WHK, Mukaka M, Callery JJ, Llewelyn MJ, Cruz CV, Dhorda M, Ngernseng T, Waithira N, Ekkapongpisit M, Watson JA, Chandna A, Nelwan EJ, Hamers RL, Etyang A, Beg MA, Sow S, Yavo W, Allabi AC, Basnyat B, Sharma SK, Amofa-Sekyi M, Yonga P, Adler A, Yuentrakul P, Cope T, Thaipadungpanit J, Rienpradub P, Imwong M, Abdad MY, Blacksell SD, Tarning J, Goudjo FF, Dossou AD, Konat�-Tour� A, Assi SB, Ouffou� K, Nasronudin N, Rachman BE, Romadhon PZ, Dewanto DD, Heryana MO, Novi T, Pasaribu AP, Mutiara M, Nasution MPR, Khairunnisa K, Dalimunthe FA, Airlangga E, Fahrezzy A, Subronto Y, Ananda NR, Rahardjani M, Rimainar A, Lucinde RK, Timbwa M, Onyango OE, Agutu C, Akech S, Hamaluba M, Kipyego J, Ngachi O, Haidara FC, Traor� OY, Diarra F, Khanal B, Dahal P, Shrestha S, Rijal S, Kabore Y, Adehossi E, Guindo O, Qamar FN, Kazi AM, Woodrow CJ, Laird S, Cheeba M, Ayles H, Cheah PY, Taylor WRJ, Batty EM, Chotivanich K, Pukrittayakamee S, Phumratanaprapin W, von Seidlein L, Dondorp A, Day NPJ, White NJ
PLoS Med, (2024). 21:e1004428

A Phase I trial of Non-invasive�Ventilation�and seizure prophylaxis with levetiracetam In�Children with�Cerebral Malaria Trial (NOVICE-M Trial).Maitland K, Obonyo N, Hamaluba M, Ogoda E, Mogaka C, Williams TN, Newton C, Kariuki SM, Gibb DM, Walker AS, Connon R, George EC
Wellcome Open Res, (2024). 9:281

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, F�rle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R, Osier FHA
Immunity, (2024). 57:1215-1224

Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.Kiguli S, Olupot-Olupot P, Hamaluba M, Giallongo E, Thomas K, Alaroker F, Opoka RO, Tagoola A, Oyella S, Nalwanga D, Nabawanuka E, Okiror W, Nakuya M, Amorut D, Muhindo R, Mpoya A, Mnjalla H, Oguda E, Williams TN, Harrison DA, Rowan K, Briend A, Maitland K
EClinicalMedicine, (2024). 72:102640

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS, Dicko A, Tinto H, Ou�draogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS
Lancet, (2024). 403:533-544

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).Maitland K, Hamaluba M, Obonyo N, Oguda E, Mogoka C, Williams TN, Chaponda M, Miti S, Kamavu LK, Jonathan Gwasupika J, Connon R, Gibb DM, Dondorp A, Day N, White N, Walker AS, George EC
Wellcome Open Res, (2023). 8:484

Safety and immunogenicity of varied doses of R21/Matrix-M� vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang S, Datoo MS, Otieno E, Muiruri C, Bellamy D, Gathuri E, Ngoto O, Musembi J, Provstgaard-Morys S, Stockdale L, Aboagye J, Woods D, Lawrie A, Roberts R, Keter K, Kimani D, Ndungu F, Kapulu M, Njau I, Orindi B, Ewer KJ, Hill AVS, Bejon P, Hamaluba M
Wellcome Open Res, (2023). 8:450

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G
Wellcome Open Res, (2023). 8:182

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.Downs LO, Campbell C, Abouyannis M, Otiende M, Kapulu M, Obiero CW, Hamaluba M, Ngetsa C, Andersson MI, Githinji G, Warimwe G, Baisley K, Scott JAG, Matthews PC, Etyang A
J Virus Erad, (2023). 9:100355

[A global core outcome measurement set for snakebite clinical trials].Abouyannis M, Esmail H, Hamaluba M, Ngama M, Mwangudzah H, Mumba N, Yeri BK, Mwalukore S, Alphan HJ, Aggarwal D, Alcoba G, Cammack N, Chippaux JP, Coldiron ME, Guti�rrez JM, Habib AG, Harrison RA, Isbister GK, Lavonas EJ, Martins D, Ribeiro I, Watson JA, Williams DJ, Casewell NR, Walker SA, Lalloo DG
Med Trop Sante Int, (2023). 3:mtsi.v3i3.2023.421